With a global focus on integrative neuroscience, (including neurology and psychiatric medicines); integrative oncology, (encompassing oncotherapy and supportive-care treatments); and vascular/immunological reaction, Japanese pharma company Eisai Co Ltd has announced that it is set to partner with Merck & Co.
Where is Lenvima made?
EISAI LAUNCHES LENVIMA® (LENVATINIB) IN CHINACOMMENCES PROVIDING THE FIRST NEW THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN CHINA IN ALMOST A DECADE. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its Chinese subsidiary Eisai China Inc.
How much do Eisai reps make?
Eisai Salary FAQs The average salary for a Pharmaceutical Sales Representative is $63,977 per year in United States, which is 38% lower than the average Eisai salary of $104,119 per year for this job.
How many people work at Eisai?
Eisai Co., Ltd. (Tokyo) is a leading global research and development based pharmaceutical company with approximately 10,000 employees worldwide and 14 drug discovery centers globally. Our U.S. headquarters are located in Woodcliff Lake, N.J. with commercial operations, clinical development and corporate functions.
Does Lenvima cause hair loss?
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away: Hair loss.
What is the drug Lenvima used to treat?
LENVIMA is used along with another medicine called everolimus to treat advanced renal cell carcinoma (RCC), a type of kidney cancer, after one course of treatment with another anti-cancer medicine. LENVIMA is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgery.
How does Lenvima affect the thyroid?
LENVIMA impairs exogenous thyroid suppression. In DTC, 88% of patients had baseline thyroid stimulating hormone (TSH) level ≤0.5 mU/L. In patients with normal TSH at baseline, elevation of TSH level >0.5 mU/L was observed post baseline in 57% of LENVIMA-treated patients.
Can Lenvima be discontinued?
Based on the type and/or severity of the adverse reaction, LENVIMA may be interrupted, reduced and/or discontinued. Based on its mechanism of action and data from animal reproduction studies, LENVIMA can cause fetal harm when administered to a pregnant woman.
How common are hemorrhagic events with Lenvima?
In DTC, RCC, and HCC clinical trials, hemorrhagic events, of any grade, occurred in 29% of the 799 patients treated with LENVIMA as a single agent or in combination with everolimus. The most frequently reported hemorrhagic events (all grades and occurring in at least 5% of patients) were epistaxis and hematuria.
